Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $8.32
Previous CloseN/A
Volume358.39K
Average Volume (3M)874.44K
Market Cap
$84.42M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 13, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding42,853,737
10 Day Avg. Volume821,864
30 Day Avg. Volume874,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside308.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesThe company received EU and UK Marketing Authorization for LYTENAVA for the treatment of wet AMD, with commercial launches in Europe planned to start in the first half of 2025.
Regulatory ApprovalThe FDA agreed to the Special Protocol Assessment for additional trials, indicating a path forward for BLA approval.
Strategic PartnershipsOutlook has entered into a strategic collaboration with Cencora to support the global commercial launch of Lytenava.
Bears Say
Clinical Trial ResultsONS-5010 missed the primary endpoint of non-inferiority at week 8 set forth in the special protocol assessment with the FDA.
Regulatory ChallengesThe FDA issued a Complete Response Letter (CRL) for ONS-5010 due to several CMC issues and a lack of substantial evidence.
Regulatory UncertaintyIt remains unclear how much weight the FDA will place on the finding of non-inferiority margin at week 12, as the 8-week readout was the only preset endpoint of the NORSE 8 study.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $8.32 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $84.42M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2025 which is in 11 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.543 by $0.143.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 42,853,737 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.543. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (308.16% Upside)
$8.00 (308.16% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
-67.68%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$8.00
▲(308.16%Upside)
Technical Analysis
Ownership Overview
32.94% Insiders
2.93% Mutual Funds
0.06% Other Institutional Investors
61.61% Public Companies and
Individual Investors